MDA-MB-231 Cells

The MDA-MB-231 cell line is a widely used model in breast cancer research. Derived from a human breast adenocarcinoma, these cells are characterized by their aggressive and invasive nature, making them an ideal model for studying triple-negative breast cancer (TNBC). MDA-MB-231 cells lack estrogen receptors (ER), progesterone receptors (PR), and HER2 amplification, which are typical markers used to classify and treat breast cancers. Consequently, these cells are resistant to hormonal therapies, reflecting the clinical challenges faced in managing TNBC. Their mesenchymal-like phenotype and ability to form tumors in immunocompromised mice further contribute to their utility in cancer research.

Genetically, MDA-MB-231 cells harbor mutations in key oncogenes and tumor suppressor genes such as TP53, KRAS, and BRAF. These genetic alterations play a crucial role in driving their malignancy and metastatic potential. Researchers use this cell line to investigate the molecular mechanisms underlying cancer progression, metastasis, and drug resistance. MDA-MB-231 cells are also employed in high-throughput screening for potential therapeutic agents, as their aggressive behavior provides a stringent test for new anti-cancer drugs. The cell line’s robust response to various stimuli makes it an invaluable tool for deciphering the complex biology of triple-negative breast cancer.